Battery X Metals validates EV battery rebalancing technology through successful real-world trials
Battery X Metals (CSE:BATX) announced a major milestone in the development of its next-generation lithium-ion battery rebalancing technology
The system successfully rebalanced all cells to 4.20 volts, recovering 1.95 ampere-hours of capacity—a 3.9 per cent increase in usable energy
The system is designed for both repair and second-life repurposing of lithium-ion batteries, supporting sustainability goals and reducing the need for costly replacements
Battery X Metals stock (CSE:BATX) last traded at $0.33
Battery X Metals (CSE:BATX) announced a major milestone in the development of its next-generation lithium-ion battery rebalancing technology. Its wholly owned subsidiary, Battery X Rebalancing Technologies Inc., has successfully validated the core innovations described in its provisional patent applications filed with the United States Patent and Trademark Office (USPTO) through a series of real-world preliminary trials.
The company's second-generation rebalancing platform, known as Prototype 2.0 (pictured above), demonstrated exceptional performance in restoring lost capacity in electric vehicle (EV) battery packs due to cell-level imbalances. These trials mark a significant step forward in Battery X's mission to extend the lifespan of EV batteries and reduce long-term ownership costs for consumers and fleet operators.
In one trial, Prototype 2.0 was tested on a 96-cell battery pack from a Nissan Leaf—one of the most common out-of-warranty EV models in the U.S. Despite only minor voltage imbalances, the system successfully rebalanced all cells to 4.20 volts, recovering 1.95 ampere-hours of capacity—a 3.9 per cent increase in usable energy. This result highlights the precision and scalability of the technology, even in relatively healthy battery packs.
A second trial involved a 144-cell battery pack from a fully electric Class 3 commercial vehicle exhibiting significant imbalance. Prototype 2.0 recovered 66.3 ampere-hours, representing a 37.7 per cent recovery of the pack's rated capacity. The system achieved 100 per cent recovery of imbalance-induced capacity loss, demonstrating its robustness under more demanding conditions and its applicability to commercial EV platforms.
'The trials are confirming exactly what we filed with the USPTO,' Massimo Bellini Bressi, CEO of Battery X Metals said in a media release. 'To see both passenger and commercial electric vehicle battery platforms respond with full imbalance-related capacity recovery proves our technological innovations work-and it works where it matters most: in real-world environments with real-world degradation caused by battery cell imbalance.'
The company's proprietary hardware and software platform includes advanced diagnostic tools capable of assessing battery State-of-Health (SoH) and identifying degradation patterns. The system is designed for both repair and second-life repurposing of lithium-ion batteries, supporting sustainability goals and reducing the need for costly replacements.
Battery X's technology has also been independently validated by the National Research Council (NRC) of Canada. In a controlled test, the system successfully rebalanced a 15-cell LiFePO4 battery module, recovering nearly all capacity lost due to artificially induced imbalances.
With global EV sales reaching 17.1 million units in 2024 and projections indicating that nearly 40 million EVs will fall out of warranty by 2031, the need for cost-effective battery maintenance solutions is growing rapidly. Battery X Rebalancing Technologies aims to position itself as a first mover in this emerging market.
Looking ahead, the company plans to expand its validation program to include a broader range of EV battery chemistries and configurations. These efforts will support commercialization and market readiness for Prototype 2.0 across both consumer and fleet-based applications.
Battery X Rebalancing Technologies' innovations represent the culmination of years of research and development and underscore the company's commitment to supporting the global transition to sustainable electric mobility.
Battery X Metals Inc. is an energy transition resource exploration and technology company committed to advancing domestic and critical battery metal resource exploration and developing next-generation proprietary technologies.
Battery X Metals stock (CSE:BATX) last traded at $0.33 and has risen 266.67 per cent since the year began and 17.65 per cent since this time last year.
Join the discussion: Find out what everybody's saying about this stock on the Battery X Metals Bullboard, and check out the rest of Stockhouse's stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
CUPANI METALS CLOSES 1ST TRANCHE OF FINANCING FOR PROCEEDS OF $2.9M
TORONTO, June 20, 2025 /CNW/ - CUPANI METALS CORP. (" CUPANI" or the " Company") (CSE: CUPA) (OTCQB: CUPIF) is pleased to announce that it closed a first tranche of the previously announced non-brokered private placement financing for aggregate gross proceeds of C$2,893,014.30 (the " Offering") comprised of the issuance of: (i) 9,181,746 flow-through units (the " FT Units") of the Company at $0.175 per FT Unit (ii) 5,193,750 charity flow-through units (the " Charity FT Units") of the Company at $0.245 per Charity FT Unit, and (iii) 85,875 hard dollar units of the Company (the " HD Units" and together with the FT Units and Charity FT Units, the " Offered Units") at $0.16 per HD Unit. Brian Bosse, CEO of the Company commented on today's news: " We are very excited about the level of interest shown with respect to the closing of this first tranche of Offering and expect to close a second tranche on or about June 26 to raise up to the maximum of an aggregate of $4M, as disclosed on the press release of the Company dated May 16, 2025 and May 21, 2025. Cupani has very high insider ownership and I am happy to see that it continues via CFO Bryan Loree's $150,500 purchase in this tranche. Funds from this tranche are already at work in our 2025 summer exploration." Each Charity FT Unit and FT Unit consisted of one common share of the Company qualifying as a "flow-through share" for purposes of the Income Tax Act (Canada) (the " Tax Act") and one half of one common share purchase warrant exercisable at $0.30 at any time prior to the day that is 24 months from the Closing Date, subject to the terms and provisions of an acceleration clause. Each HD Unit consisted of one common share of the Company and one half of one common share purchase warrant exercisable on the same terms as the warrants comprising the Charity FT Units and FT Units. The gross proceeds from the Offering will be used by the Company on its 100% owned Blue Lake/Retty Lake exploration project exploration project as well as for general working capital purposes. The gross proceeds from the common shares comprising the Charity FT Units and FT Units will be used by the Company for "Canadian exploration expenses" that are "flow-through critical mineral mining expenditures" (as such terms are defined in the Tax Act). The Offered Units were issued by way of a private placement pursuant to exemptions from prospectus requirements under applicable securities laws. The securities issued pursuant to the Offering are subject to resale restrictions, including a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. CFO and Director Bryan Loree, an insider of the Company, participated in the Offering by acquiring 860,000 FT Units. The participation will constitute a related party transaction, but is exempt from the formal valuation and minority approval requirements of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (" MI 61-101") as the Company's securities are not listed on any of the stock exchanges listed in Section 5.5(b) of MI 61-101 and the fair market value of the securities issued to Mr. Loree does not exceed 25% of the Company's market capitalization. In connection with the Offering, the Company paid aggregate cash finder's fees of $71,092.51 and issued 12,500 compensation HD Units to certain finders. Each finder warrant underlying the compensation HD Units entitles the holder to purchase one Share of the Company at $0.30 per Share for a period of 24 months. Grant of Stock Options The Company also announces that it grants 250,000 incentive stock options to a consultant of the Company at an exercise price of $0.16 for a period of five (5) years to purchase up to the equal number of common shares in the capital the Company, in accordance with and subject to the Company's Omnibus Long-Term Incentive Plan. About CUPANI CUPANI Metals Corp. provides shareholders with long-term capital growth exposure by investing in mineral exploration properties and other assets. The Company is listed on the CSE under the symbol "CUPA". To learn more about the Company please visit NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY OF THE SECURITIES IN THE UNITED STATES. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE " U.S. SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER OR SALE OF SECURITIES IN THE UNITED STATES. Forward-Looking Information Certain of the statements made and information contained herein is "forward-looking information" within the meaning of National Instrument 51-102 – Continuous Disclosure Obligations of the Canadian Securities Administrators. These statements and information are based on facts currently available to the Company and there is no assurance that actual results will meet management's expectations. Forward-looking statements and information may also be identified by such terms as "anticipates", "believes", "targets", "estimates", "plans", "expects", "may", "will", "could" or "would". While the Company considers its assumptions to be reasonable as of the date hereof, forward-looking statements and information are not guarantees of future performance and readers should not place undue importance on such statements as actual events and results may differ materially from those described herein. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking statements in this news release include without limitation, statements with respect to the anticipated use of proceeds from the Offering and the closing of a subsequent tranche to raise gross proceeds of up to $4M. All forward-looking information contained in this press release is given as of the date hereof, and is based on the opinions and estimates of management and information available to management as of the date hereof. These statements are based upon assumptions that are subject to significant risks and uncertainties, including risks regarding commodity prices, market conditions, availability of financing to the Company on acceptable terms, gross proceeds are used in accordance with the Tax Act, general economic factors, and the equity markets generally. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance of the Company may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, they can give no assurances that the expectations of any forward-looking statements will prove to be correct. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as may be required by applicable securities laws.
Cision Canada
12 hours ago
- Cision Canada
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces that it has amended the terms of its brokered private placement LIFE financing (the " Offering") previously announced on May 30, 2025, and filed an amended offering document (the " Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units (" Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
Cision Canada
a day ago
- Cision Canada
CSA revises "venture issuer" definition and codifies form of proxy requirement Français
VANCOUVER, BC, June 19, 2025 /CNW/ - The Canadian Securities Administrators (CSA) today published amendments and changes to certain National Instruments and Policies to address a number of matters, including the creation of a Senior Tier by the Canadian Securities Exchange (CSE). The Senior Tier of the CSE is intended for non-venture issuers, with requirements that align with a non-venture exchange. The amendments and changes revise the definition of "venture issuer" to exclude CSE Senior Tier issuers and allow them to be treated the same way under securities legislation as issuers listed on other non-venture exchanges. The amendments and changes also: Expand certain exemptions and eligibility requirements to include the CSE, so that they apply to that exchange in the same manner as for other non-venture exchanges. Codify the January 31, 2023, blanket orders issued by CSA members that exempt reporting issuers incorporated under the Canada Business Corporations Act from the requirement regarding the voting options on the proxy form in uncontested director elections. Reflect the name change of the former Aequitas NEO Exchange Inc. to Cboe Canada Inc. Reflect the name change of the former PLUS markets to AQSE Growth Market. Remove the requirement for escrow agreements required under securities legislation to be signed, sealed and delivered by securityholders in the presence of a witness. Provided all necessary approvals are obtained, the amendments and changes will take effect on September 19, 2025. The CSA, the council of the securities regulators of Canada's provinces and territories, co-ordinates and harmonizes regulation for the Canadian capital markets. For media inquiries, please contact: For investor inquiries, please contact your local securities regulator.
